BioXcel Therapeutics (BTAI) Net Cash Flow (2017 - 2026)

BioXcel Therapeutics' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$11.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 1098.88% year-over-year to -$11.6 million; the TTM figure through Mar 2026 stood at -$13.8 million (up 67.93% YoY), while the FY2025 annual figure was -$1.1 million, up 96.9% from the prior year.
• Net Cash Flow was -$11.6 million for Q1 2026 at BioXcel Therapeutics, down from -$8.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $18.7 million in Q3 2025 to a low of -$38.6 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$16.6 million across 5 years, with a median of -$15.9 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow sank 3202.64% in 2023, then surged 218.01% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$38.6 million in 2022, then surged by 35.89% to -$24.7 million in 2023, then jumped by 57.43% to -$10.5 million in 2024, then climbed by 18.7% to -$8.6 million in 2025, then sank by 35.2% to -$11.6 million in 2026.
• The last three Net Cash Flow figures came in at -$11.6 million (Q1 2026), -$8.6 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.